Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2006-07-18
2009-06-30
Jones, D. L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S001110, C424S001650, C424S001810, C424S009100
Reexamination Certificate
active
07553478
ABSTRACT:
A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.
REFERENCES:
patent: 3813404 (1974-05-01), Clarke et al.
patent: 5493026 (1996-02-01), Elmaleh et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5500343 (1996-03-01), Blum et al.
patent: 5621133 (1997-04-01), DeNinno et al.
patent: 5747523 (1998-05-01), Jackson
patent: 5760055 (1998-06-01), Davies
patent: 5770180 (1998-06-01), Madras et al.
patent: 5874090 (1999-02-01), Baker et al.
patent: 5902797 (1999-05-01), Bell et al.
patent: 5948933 (1999-09-01), Meltzer et al.
patent: 6008227 (1999-12-01), Davies et al.
patent: 6011070 (2000-01-01), Froimowitz et al.
patent: 6171576 (2001-01-01), Meltzer et al.
patent: 6350758 (2002-02-01), Kozikowski et al.
patent: 6353105 (2002-03-01), Meltzer et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6417221 (2002-07-01), Meltzer et al.
patent: 6531483 (2003-03-01), Kuhar et al.
patent: 6548041 (2003-04-01), Meltzer et al.
patent: 6670375 (2003-12-01), Meltzer et al.
patent: 7081238 (2006-07-01), Madras et al.
patent: 7105678 (2006-09-01), Meltzer et al.
patent: WO 94/04146 (1994-03-01), None
patent: WO 97/16210 (1997-05-01), None
patent: WO 97/40859 (1997-11-01), None
patent: WO 98/24788 (1998-06-01), None
patent: WO 99/07359 (1999-02-01), None
Madras et al (Dec. 1998), Synapse, vol. 29, No. 2, pp. 105-115.
J.M. Swanson, et al., “Attention-deficit disorder and hyperkinetic disorder,” Lancet, XX, XX vol. 351, No. 9100, Feb. 7, 1998, pp. 438-440, XP004265114.
K.H. Krause, et al., “Increased striatal dopamine transporter in adult patients with attention deficit disorder: effects of methylphenidate as measured by single photon emission computed topography,” Neuroscience Letters, vol. 285, No. 2, May 12, 2000, pp. 107-110, XP002239034.
D. Dougherty, et al., “Dopamine transporter density in patients with attention deficit hyperactivity disorder,” Lancet, XX, XX, vol. 354, No. 9196, Dec. 18, 1999, pp. 2132-2133, XP004263271.
I.D. Waldman, et al., “Association and Linkage of the dopamine transporter gene and attention-Deficit hyperactivity disorder in children: Heterogeneity owing to diagnostic subtype and severity,” American Journal of Human Genetics, Dec. 1998, vol. 63, No. 6, pp. 1767-1776, XP-002239035, (Abstract).
A.J. Fischman, et al., “Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters,” Synapse (New York, NY), Jun. 1998, vol. 29, No. 2, pp. 128-141, XP-002239036, (Abstract).
Ernst et al., “High Midbrain [1° F]DOPA Accumulation in Children With Attention Decifict H˜eractivi Disorder”, Am J Ps chiat, 156:8, Au', Vust 1999.
Ernst et al., “DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A [Fluorine- 18]Fluorodopa Positron Emission Tomographic Study”, The Journal of Neuroscience, Aug. 1, 1998, 18(15):5901-5907.
Arnold et al., “National Institute of Mental Health Collaborative Multimodal Treatment. Study of Children with ADHD (the MTA). Design Challenges and Choices,” Arch. Gen. Psychiatry, 54(9):865-70(1997.
Babich et al., “C-11 Methyl-3p-[4-fluorophenyl]-N-iodo-E-allyl-IaH-5aH--nortropane-2(3carboxvlate: a hiehly selective DAT liaand for PET,” J. Nuclear Medicine, 39:238 (1998).
Madras et al., “Imaging the Dopamine Transporter: A Window on Dopamine Neurons. Advances in Neurodegenerative Disorders,” J. Marwah, H. Teitelbaum, Eds., vol. 1. Parkinson's Disease, pp. 229-253(1998).
Meltzer, et al., “Substituted 2-Phenyltropane Analogs of Cocaine; Synthesis, Inhibition of Binding at Cocaine Recognition Sites and Positron Emission Tomography (PET) Imaging,” J. Med. Chem., 36:855-862(1993).
Sano et al., “A 40-Nucleotide Repeat Polymorphism in the Human Dopamine Transporter Gene,” Hum. Genet., 91:405-406 (1993).
Seeman et al., “Anti-Hyperactivity Medication: Methylphenidate and Amphetamine,” Mol.Psychiatry, 3(5):386-96 (1998).
Thapar et al., “Genetic Basis of Attention Deficit and Hyperactivity,” Br. J. Psychiatry, 174:105-11 (1999).
Volkow et al., “Dopamine Transporter Occupancies in the Human Brian Induced by Therapeutic Doses of Oral Meth I whenidate,” Am. J.Psychiatry, 155:1325-31 1998).
Waldman et al., “Association and Linkage of the Dopamine Transporter Gene and Attention-Deficit Hyperactivity Disorder in Children: Heterogeneity Owing to Diagnostic Subtype and Severity,” Am. J. Hum. Genet, 639(6):1767-76 1998).
Wilens et al., “The Stimulants,” Psychiatr. Clin North Am., 15(1):191-222 (1992).
Bonab et al., “ Determination of Dopamine Transporter Density and Affinity Using High and LowSpecific ActivityInjections of C-11 Altro ane,” J. Nuclear Medicine, 39:66 (1998).
Bonab et al., “Estimation of C-11-CFT Binding Potential by Iterative Fitting (IF) and Comparison with Reference Region Graphical (RRG) and Reference Fitting (RF) in Monkeys,” J. Nuclear Medicine, 39:167 1998).
Canfield et al., “Autoradiographic Localization of Cocaine Binding Sites by [3H]CFT ([3H]WIN 35,428) in theMonkeyBrain, ”Synapse, 6(2):189-95 (1990).
Comings et al., “Polygenic Inheritance of Tourette Syndrome, Stuttering, Attention Deficit Hyperactivity, Conduct, and Oppositional Defiant Disorder: The Additive and Substractive Effect of the Three Dopaminergic Genes—DRD2, D beta H, and DAT1,” Am. J. Med. Genet, 67(3):26488(1996).
Cook et al., “Association of Attention-Deficit Disorder and the Dopamine Transporter Gene,” Am. J. Hum. Genet., 56(4):993-8 (1995).
Daly et al., “Mapping Susceptibility Loci in Attention Deficit Hyperactivity Disorder: Preferential Transmission of Parental Alleles at DAT1, DBH and DRD5 to Affected Children,” Mol. Psychiatry, 4(2):192-6 1999).
Fischman et al., “SPECT Imaging of Dopamine Transporter Sites in Normal and MPTP-Treated RhesusMonkeys,” J. Nuclear Medicine, 38(1):144-50 1997.
Fischman et al., “Rapid Detection of Parkinson's Disease with Altropane, a SPECT Ligand,”Synapse, 29:128-41 1998).
Gill et al., “Confirmation of Association Between Attention Deficit Hyperactivity Disorder and aDopamine Transporter Polymorphism,” Mol.Psychiatry, 2(4):311-3 (1997).
Greenhill et al., “Stimulant Medications,” J. Am. Acad. Child Adolesc. Psychiatry, 38(5):503-12 (1999).
Kaufman et al., “Distribution of Cocaine Recognition Sites in Monkey Brain: 1. In Vitro Autoradio ra h with 3H CFT,”Synapse, 9(3):177-87 (1991).
Kaufinan et al., “Distribution of Cocaine Recognition Sites in Monkey Brain: II. Ex Vivo Autoradio a h with 3H CFT and 125I RTI-55,”Synapse, 12(2):99-111 (1992).
Madras et al., “Technepine: A High-Affinity 99m-Technetium Probe to Label the DopamineTransporterin Brain b SPECTImaging”Synapse, 22(3):239-46 (1996).
Madras et al., “N-Modified Fluorophenyltropane Analogs of Cocaine with High Affinity for CocaineReceptors,” Pharmacol. Biochem. Behav., 35(4):949-53 1990.
Madras et al., “Effects of Cocaine and Related Drugs in Nonhuman Primates. I. [3H]CocaineBindingSites in Caudate-Putamen,” J. Pharmacol.Ex p. Ther., 251(1):131-41 (1989).
Madras et al., “[′″I]Altropane, a SPECT Imaging Probe for Dopamine Neurons: I. DopanineTransporter Bindingin Nonhuman Primate Brain,”Synapse, 29:93-104 1998).
Madras et al., “[′″I]Altropane, a SPECT Imaging Probe for Dopamine Neurons: II. In Vitro and Ex V
Fischman Alan J.
Madras Bertha K.
Meltzer Peter C.
Edwards Angell Palmer & & Dodge LLP
Jones D. L.
Neuner George W.
Organix Inc.
President and Fellows of Harvard College
LandOfFree
Methods for diagnosing and monitoring treatment ADHD by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosing and monitoring treatment ADHD by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing and monitoring treatment ADHD by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4146610